Takeda’s Adzynma, BeiGene’s Sonrotoclax, and Avistone’s Andatinib Set for Priority Review in China
The website of China’s Center for Drug Evaluation (CDE) indicates that Takeda’s (TYO: 4502) Adzynma...
Takeda
Belief BioMed and Takeda Win NMPA Approval for China’s First Hemophilia B Gene Therapy
China-based gene therapy specialist Belief BioMed Inc. and Takeda’s (NYSE: TAK, TYO: 4502) China unit...
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...
Takeda Partners with BridGene to Develop Immunology and Neurology Drug Candidates
Japan-based Takeda Pharmaceutical Company (NYSE: TAK, TYO: 4502) announced a partnership with US-based BridGene Biosciences,...
Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period...
Takeda and Fudan University’s IMI Launch AI-Based Rare Disease Screening and Diagnosis Project
Japan-headquartered Takeda (TYO: 4502) and the Intelligent Medicine Institute (IMI) at Fudan University have jointly...
Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for...
HutchMed to Receive Milestone Payment as Takeda’s Fruzaqla Gets Reimbursement Nod in Spain
China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) is poised to receive another milestone payment...
Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings...
Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development
US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda...
HutchMed Anticipates Milestone Payment as Takeda Launches Fruzaqla in Japan for CRC
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a milestone payment...
Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies
US-based Alloy Therapeutics Inc. has announced a strategic partnership with Japan-headquartered Takeda Pharmaceutical Co., Ltd...
AbbVie’s Elahere Receives EC Approval for FRα-Positive Ovarian Cancer Treatment
US-based AbbVie (NYSE: ABBV) has announced the European Commission (EC) approval for its antibody drug...
ATLATL and Takeda Enter MoU to Collaborate on Early-Stage Drug Development and Innovation
ATLATL, an innovation incubator and global life science research and development (R&D) platform, has signed...
Takeda Reports 5% YOY Revenue Growth and Upgrades Forecasts for Fiscal 2024
Takeda (TYO: 4502) has released its earnings results for the first half of fiscal year...
HutchMed to Receive $20 Million Milestone Payment from Takeda for Fruzaqla Sales
China-based HutchMed (China) Ltd (NASDAQ: HCM; HKG: 0013) is poised to receive a USD 20...
Takeda Prepares to File Dengue Fever Vaccine for US Approval, Expanding Global Regulatory Reach
Takeda Pharmaceutical, a leading Japanese pharmaceutical company listed on the NYSE (NYSE: TAK), is reportedly...
Takeda’s Vonicog Alfa Receives NMPA Approval for Von Willebrand Disease Treatment in China
Takeda Pharmaceutical Company Limited (TYO: 4502 / NYSE: TAK), a leading Japanese pharmaceutical company, has...
Takeda to Slash 1,000 US Jobs as Part of Broader Restructuring Effort
Japanese pharmaceutical giant Takeda Pharmaceuticals (TYO: 4502 / NYSE: TAK) has confirmed reports from Nikkei...
Takeda Reports Q1 FY2024 Earnings with Growth in Key Therapies and New Launches
Japanese pharmaceutical company Takeda (TYO: 4502, NYSE: TAK) has announced its financial results for the...